Dr. Kapil Mehta
The University of Texas MD Anderson Cancer Center
Department of Experimental Therapeutics
Development of resistance to a wide range of chemotherapeutic drugs and metastasis pose major impediment in successful treatment of cancer. Our laboratory is investigating intrinsic pathways/proteins that are deregulated in cancer cells and contribute to the development of these phenotypes. Another area of research in our lab is targeted delivery of drugs, using liposomes as delivery system.
The tutorial in this laboratory will train individuals in the areas of cancer/cell biology, signal transduction, immunochemical, biochemical and molecular biology techniques.
Verma A, Mehta K (2007) Tissue Transglutaminase-mediated activation of nuclear transcription factor-kB as a target for cancer treatment. Curr Cancer Drug Targets. 7:559-565.
Verma A, Mehta K (2007) Mechanisms of sensitivity and resistance: perspectives for improvement of therapy. Drug Resistance Updates 10:144-151.
Verma A, Koul D., Guha S, Wang H, Mehta K (2008) Transglutaminase-mediated regulation of PTEN in pancreatic cancer cells. Clin Cancer Res 14:1997-2005.
Verma A, Guha S, Diagaradjane P, Kunnumakkara AB, Sanguino AM, Berestein GL, Sood AK, Aggarwal BB, Mehta K (2008) Tissue transglutaminase as a therapeutic target for inhibiting growth and metastasis of pancreatic ductal adenocarcinoma. Clin Cancer Res 14:2476-2483.
Hwang JY, Mangala LS, Fok et al. (2008) Clinical and Biological Significance of tissue transglutaminase in ovarian cancer. Cancer Res 68:5849-58.
Office: MDA 4SCR3.1006 (Unit 1950)
Ph.D. - Postgraduate Institute-Medical Education/Research - 1981